BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 10652564)

  • 1. The Brca1 and Brca2 proteins and tumor pathogenesis.
    Ingvarsson S
    Anticancer Res; 1999; 19(4B):2853-61. PubMed ID: 10652564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
    Armes JE; Trute L; White D; Southey MC; Hammet F; Tesoriero A; Hutchins AM; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ
    Cancer Res; 1999 Apr; 59(8):2011-7. PubMed ID: 10213514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons learned from BRCA1 and BRCA2.
    Zheng L; Li S; Boyer TG; Lee WH
    Oncogene; 2000 Dec; 19(53):6159-75. PubMed ID: 11156530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
    De Benedetti VM; Radice P; Pasini B; Stagi L; Pensotti V; Mondini P; Manoukian S; Conti A; Spatti G; Rilke F; Pierotti MA
    Hum Mutat; 1998; 12(3):215. PubMed ID: 10660329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer.
    Foster KA; Harrington P; Kerr J; Russell P; DiCioccio RA; Scott IV; Jacobs I; Chenevix-Trench G; Ponder BA; Gayther SA
    Cancer Res; 1996 Aug; 56(16):3622-5. PubMed ID: 8705994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.
    Crook T; Brooks LA; Crossland S; Osin P; Barker KT; Waller J; Philp E; Smith PD; Yulug I; Peto J; Parker G; Allday MJ; Crompton MR; Gusterson BA
    Oncogene; 1998 Oct; 17(13):1681-9. PubMed ID: 9796697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations.
    Khoo US; Ngan HY; Cheung AN; Chan KY; Lu J; Chan VW; Lau S; Andrulis IL; Ozcelik H
    Hum Mutat; 2000 Jul; 16(1):88-9. PubMed ID: 10874312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
    Gonzalez R; Silva JM; Dominguez G; Garcia JM; Martinez G; Vargas J; Provencio M; España P; Bonilla F
    Br J Cancer; 1999 Oct; 81(3):503-9. PubMed ID: 10507777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women.
    Noguchi S; Kasugai T; Miki Y; Fukutomi T; Emi M; Nomizu T
    Cancer; 1999 May; 85(10):2200-5. PubMed ID: 10326698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland.
    van Der Looij M; Wysocka B; Brozek I; Jassem J; Limon J; Olah E
    Hum Mutat; 2000 May; 15(5):480-1. PubMed ID: 10790213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
    Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
    Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2.
    Ramus SJ; Friedman LS; Gayther SA; Ponder BA; Bobrow L; van der Looji M; Papp J; Olah E
    Nat Genet; 1997 Jan; 15(1):14-5. PubMed ID: 8988162
    [No Abstract]   [Full Text] [Related]  

  • 15. BRCA2 mutations in primary breast and ovarian cancers.
    Lancaster JM; Wooster R; Mangion J; Phelan CM; Cochran C; Gumbs C; Seal S; Barfoot R; Collins N; Bignell G; Patel S; Hamoudi R; Larsson C; Wiseman RW; Berchuck A; Iglehart JD; Marks JR; Ashworth A; Stratton MR; Futreal PA
    Nat Genet; 1996 Jun; 13(2):238-40. PubMed ID: 8640235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
    Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
    Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers.
    Phillips KA
    J Clin Oncol; 2000 Nov; 18(21 Suppl):107S-12S. PubMed ID: 11060337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.
    Yazici H; Bitisik O; Akisik E; Cabioglu N; Saip P; Muslumanoglu M; Glendon G; Bengisu E; Ozbilen S; Dincer M; Turkmen S; Andrulis IL; Dalay N; Ozcelik H
    Br J Cancer; 2000 Sep; 83(6):737-42. PubMed ID: 10952777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials.
    Levy-Lahad E; Krieger M; Gottfeld O; Renbaum P; Klein G; Eisenberg S; Lahad A; Kaufman B; Catane R
    J Cell Biochem Suppl; 2000; 34():13-8. PubMed ID: 10762009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.